DCM
CBAY

Delpha Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Delpha Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,350
Closed -$22K – 1323
2017
Q4 		$22K Buy
+2,350
New +$20.1K 0.02% 737

Other funds holding CBAY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Delpha Capital Management's CBAY Position: Q1 2018 in Review

Delpha Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2018, closing a stake of 2,350 shares — an estimated $22K sold.

Delpha Capital Management first reported a position in CBAY in Q4 2017 and held it in 1 quarter. The position peaked at $22K in Q4 2017. 107 funds tracked by Wall St. Rank hold CBAY as of Q1 2018.

  • Delpha Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 2,350 Cymabay Therapeutics shares in Q1 2018, an estimated $22K.
  • Delpha Capital Management first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Cymabay Therapeutics position peaked at $22K in Q4 2017.
  • 107 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.